Recently, the FDA approved the Therascreen PIK3CA RGQ polymerase chain reaction assay as a companion diagnostic assay to detect PIK3CA mutations in breast cancer for both tissue and liquid biopsies, bringing the role of liquid biopsy into breast cancer management. This evidence concerns the gene PIK3CA and breast carcinoma.